Abstract
Introduction
We aimed to assess the frequency, duration, and severity of area postrema syndrome (APS) during follow-up in neuromyelitis optica spectrum disorder (NMOSD) patients, as well as its association with inflammatory activity and prognostic factors of APS severity in a real-world setting.
Methods
We conducted a retrospective study on a cohort of Latin American (LATAM) NMOSD patients who had experienced APS during their follow-up. Patients from Mexico, Peru, Brazil, Colombia, Panama, Chile and Argentina patients who met 2015 NMOSD criteria were included. We evaluated data on symptom type (nausea, vomiting and/or hiccups), frequency, duration, severity (measured by APS severity scale), association with other NMOSD core relapses, and acute treatments (symptomatic and immunotherapy or plasmapheresis). Logistic regression was conducted to evaluate factors associated with APS severity (vs. mild-moderate).
Results
Out of 631 NMOSD patients, 116 (18.3%) developed APS during their follow-up. The most common APS phenotype was severe. Inflammatory activity (i.e., relapses) significantly decreased after the onset of APS. Half of the patients experienced isolated APS with a median duration of 10 days, and the most frequently used acute treatment was IV steroids. All three symptoms were present in 44.6% of the patients. APS symptoms resolved following immunotherapy. Logistic regression did not identify independent factors associated with the severity of APS.
Conclusions
Our findings indicate that 18.3% of NMOSD patients developed APS during the follow-up period, with most patients fulfilling criteria for severe APS. The inflammatory activity decreased after the onset of APS compared to the previous year.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMO Diagnosis (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189. https://doi.org/10.1212/WNL.0000000000001729
Carnero Contentti E, Correale J (2021) Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation 18(1):208. https://doi.org/10.1186/s12974-021-02249-1
Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Yoshiki T, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ (2018) Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology 91(17):e1642–e1651. https://doi.org/10.1212/WNL.0000000000006392
Iorio R, Lucchinetti CF, Lennon VA, Farrugia G, Pasricha PJ, Weinshenker BG, Pittock SJ (2013) Intractable nausea and vomiting from autoantibodies against a brain water channel. Clin Gastroenterol Hepatol 11(3):240–245. https://doi.org/10.1016/j.cgh.2012.11.021
Paviolo JP, Tkachuk VA (2020) Síndrome del área postrema aislado con anticuerpos anti-MOG, una asociación poco frecuente [Isolated area postrema syndrome with anti-MOG antibodies, a rare association]. Rev Neurol 71(3):125–126. https://doi.org/10.33588/rn.7103.2020189
DE Souza TFS (2020) A concise historical perspective of the area postrema structure and function. Arq Neuropsiquiatr 78(2):121–123. https://doi.org/10.1590/0004-282X20190118
Bertado-Cortés B, León-Castillo DA, Castro-Guerra A (2023) Clinical features and frequency of area postrema syndrome in neuromyelitis optica spectrum disorder: a single-center study in Mexico. Brain Disord 9:100068. https://doi.org/10.1016/j.dscb.2023.100068
Camara-Lemarroy CR, Burton JM (2019) Area postrema syndrome: a short history of a pearl in demyelinating diseases. Mult Scler 25(3):325–329. https://doi.org/10.1177/1352458518813105
Reynosa. Area postrema, Fisiología. Fisiología Humana. Universidad México Americana del Norte (UMAN), 4 pp
Popescu BF, Lennon VA, Parisi JE et al (2011) Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 76:1229–1237
Liu T, Li L, Guo X, Li Q, Jia D, Ma L (2022) Clinical analysis of neuromyelitis optica spectrum disease with area postrema syndrome as the initial symptom. Eur J Med Res 27(1):315. https://doi.org/10.1186/s40001-022-00949-9
Rivera VM, Hamuy F, Rivas V, Gracia F, Rojas JI, Bichuetti DB, Villa AM, Marques VD, Soto A, Bertado B, Frenk IT, Galleguillos L, Quiñones J, Ramirez DA, Caparó-Zamalloa C, Ciampi E, Lana-Peixoto MA, Rodríguez E, Zarco L, Sinay V, Armas E, Becker J, Benzadón A, Lopez E, Carnero Contentti E, Correa-Diaz EP, Diaz A, Fleitas CV, Playas G, Molina O, Rojas E, Sato D, Soto I, Céspedes JV, Correale J, Barboza A, Monterrey P, Candelario A, Tavolini DR, Parajeles A, Pujol BS, Diaz de la Fe A, Alonso R, Bolaña C, Guzman MK, Carrá A, Gamarra OG, Raggio JV, Rodriguez LC, Ramirez NE, Ordoñez L, Skromne E, Portillo LL, Canabal AP, Weiser R, Sirias V, Calderón RF, Cornejo EA, Hernández M, Quiroz JCD, Garcia LA, Cedeño CO, Martínez J, Abad-Herrera P (2021) Status of the neuromyelitis optica spectrum disorder in Latin America. Mult Scler Relat Disord 53:103083. https://doi.org/10.1016/j.msard.2021.103083
Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L, Mutch K, Levy M, Takai Y, Collongues N, Banwell B, Fujihara K, de Seze J (2014) Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 20(7):843–847. https://doi.org/10.1177/1352458513507822
Rojas JI, Carrá A, Correale J, Cristiano E, Fernández Liguori N, Alonso R, Alvez Pinheiro A, Balbuena ME, Barboza AG, Bestoso S, Blaya PA, Burgos M, Cabrera LM, Caride A, Carnero Contentti E, Cohen L, Curbelo C, Deri N, Divi P, Fiol M, Fracaro ME, Gaitán MI, Hryb J, Jacobo M, Knorre E, Leguizamon F, Giunta D, Alonso Serena M, Doldan ML, De Lio GF, Liwacki SDV, Lopez PA, Luetic G, Mainella C, Manzi R, Marrodan M, Martinez AD, Miguez J, Negrotto L, Nofal P, Parada Marcilla M, Pettinicchi JP, Silva BA, Silva E, Silveira F, Steinberg JD, Tavolini D, Tizio S, Tkachuk V, Vazquez G, Volman G, Vrech C, Ysrraelit MC, Zanga G, Garcea O, Patrucco L (2019) The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions. Mult Scler Relat Disord 32:133–137. https://doi.org/10.1016/j.msard.2019.05.004
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452. https://doi.org/10.1212/wnl.33.11.1444
Waters P, Woodhall M, O’Connor KC, Reindl M, Lang B, Sato DK, Juryńczyk M, Tackley G, Rocha J, Takahashi T, Misu T, Nakashima I, Palace J, Fujihara K, Leite MI, Vincent A (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2(3):e89. https://doi.org/10.1212/NXI.0000000000000089
Rojas JI, Gracia F, Patrucco L, Alonso R, Carnero Contentti E, Cristiano E (2021) Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America. Neurol Res 43(12):1081–1086. https://doi.org/10.1080/01616412.2021.1949686
Carnero CE (2023) Rectifying global inequities in neuromyelitis optica diagnosis and treatment: a critical view from Latin America. Mult Scler 29(10):1347–1348. https://doi.org/10.1177/13524585231190248
Tkachuk V, Balbuena Aguirre ME, Alonso R, Barboza A, Liwacki SDV, Mainella C, Rojas JI, Silva BA, Tavolini D, Zanga G, López P, Delgado Garcia G, Carnero CE (2023) Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort. Mult Scler Relat Disord 70:104485. https://doi.org/10.1016/j.msard.2022.104485
D’Souza M, Papadopoulou A, Levy M, Jacob A, Yeaman MR, Kümpfel T, Marignier R, Paul F, Brandt AU (2020) Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: results of an international survey. Mult Scler Relat Disord 41:102027. https://doi.org/10.1016/j.msard.2020.102027
Hyun JW, Kwon YN, Kim SM, Lee HL, Jeong WK, Lee HJ, Kim BJ, Kim SW, Shin HY, Shin HJ, Oh SY, Huh SY, Kim W, Park MS, Oh J, Jang H, Park NY, Lee MY, Kim SH, Kim HJ (2020) Value of area postrema syndrome in differentiating adults with AQP4 vs. MOG antibodies. Front Neurol 11:396. https://doi.org/10.3389/fneur.2020.00396
Seok JM, Cho HJ, Ahn SW, Cho EB, Park MS, Joo IS, Shin HY, Kim SY, Kim BJ, Kim JK, Cho JY, Huh SY, Kwon O, Lee KH, Kim BJ, Min JH (2017) Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: a multicenter retrospective study in Korea. Mult Scler 23(13):1748–1756. https://doi.org/10.1177/1352458516685416
Funding
This research received no specific grant from any funding agency.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Ethical standard
Ethics committee approval was obtained for each participating center, and written informed consent (according to each committee, if necessary) was obtained from all participants before data collection.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Pestchanker, C., Bertado Cortez, B., Lana Peixoto, M.A. et al. Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings. J Neurol 271, 4292–4299 (2024). https://doi.org/10.1007/s00415-024-12371-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-024-12371-8